查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1725148

2032 年尿激酶市场预测：按类型、来源、给药途径、应用、最终用户和地区进行的全球分析

Urokinase Market Forecasts to 2032 - Global Analysis By Type (Urokinase Powder and Urokinase Solution), Source, Route of Administration, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球尿激酶市场预计在 2025 年达到 20.8 亿美元，到 2032 年将达到 35 亿美元，预测期内的复合年增长率为 7.7%。

尿激酶是一种血栓溶解酶，医学上用于溶解体内的血栓。它是丝胺酸蛋白酶，最初来自人类尿液，但现在通常使用重组 DNA 技术生产。尿激酶将胞浆素原原转化为胞浆素，并作为分解纤维蛋白（血块的主要蛋白质组成）的酶。主要用于治疗肺动脉栓塞、深层静脉栓塞症、导管阻塞等。尿激酶作为纤溶酶原激活剂，在恢復阻塞血管的血流中起着重要作用，使其成为急诊和介入医学的重要治疗选择。

根据英国心臟基金会 2024 年的一篇报导，英国有 760 万人患有心臟和循环系统疾病。

血栓性疾病盛行率不断上升

由于对血栓溶解疗法的需求增加，血栓疾病的盛行率不断上升，推动了尿激酶市场的发展。尿激酶用于分解血栓，在治疗肺动脉栓塞、深层静脉栓塞症和急性心肌梗塞中发挥重要作用。随着这些疾病在全球范围内的盛行率上升，特别是在老年人口中，对​​有效的溶栓疗法的需求也日益增加。这一趋势有利于尿激酶市场并刺激其生产和应用的进一步发展。

医疗费用高昂

高昂的治疗费用严重阻碍了尿激酶市场的成长，因为它限制了患者和医疗保健提供者获得治疗的机会，尤其是在中低收入地区。如此高的治疗费用限制了尿激酶治疗方法的广泛使用，并导致对更便宜的替代疗法的需求。此外，高成本对医疗预算造成压力，阻碍了保险覆盖，并限制了广泛的临床使用，最终减缓了市场扩张并抑制了溶栓疗法的创新。

药物传输技术进步

药物输送系统的技术进步对尿激酶市场产生了重大影响，提高了其治疗效果和精确度。靶向输送机制和基于奈米粒子的配方等技术创新有望提高生物有效性并减少副作用。这些进步提高了药物针对特定部位的能力，优化了血栓和心臟病等疾病的治疗。此外，控制释放技术和个人化药物传递系统有助于改善患者的治疗效果，进而推动尿激酶市场的需求和成长。

出血併发症的风险

出血併发症的风险将严重阻碍尿激酶市场的成长。尿激酶是一种溶栓剂，极有可能引起内出血，尤其是对于有潜在疾病或服用抗凝血剂的患者。这些安全问题限制了医疗保健提供者对尿激酶的采用，并促使谨慎开药。此外，监管限制和更安全替代药物的可用性进一步限制了市场扩张，对需求和整体市场表现产生负面影响。

COVID-19的影响

COVID-19 疫情严重扰乱了尿激酶市场，导致择期手术延迟、住院人数减少以及供应链中断。在疫情高峰期，对非新冠相关治疗（包括尿激酶等溶栓药物）的需求下降。然而，随着医疗保健系统的稳定和外科手术的恢復，市场开始復苏。此外，人们对 COVID-19 患者血栓併发症的认识提高间接支持了对抗凝血和溶栓疗法的需求。

预计尿激酶溶液细分市场在预测期内将占据最大份额

预计在预测期内，尿激酶溶液部分将占据最大的市场占有率。尿激酶溶液，尤其是静脉注射和局部形式，因其能够快速溶解血栓，改善肺动脉栓塞和深层静脉栓塞症等患者的预后而受到青睐。医院和医疗机构越来越多地采用尿激酶製剂以及正在进行的研究也对该领域的市场扩张产生了积极影响。

预计深层静脉栓塞症领域在预测期内将以最高复合年增长率成长

由于血栓性疾病盛行率的上升以及对早期诊断和治疗的认识的提高，预计深层静脉栓塞症部分将在预测期内出现最高增长率。尿激酶是一种溶栓剂，广泛用于深部静脉栓塞（DVT）患者的溶栓治疗，其需求日益增长。医疗基础设施的进步和人口老化也促进了市场扩张。这一趋势使 DVT 成为尿激酶市场持续成长和创新的关键驱动力。

比最大的地区

预计亚太地区将在预测期内占据最大的市场占有率。这是由于心血管疾病的增加、认识的提高以及获得先进治疗的机会的改善推动了需求。这种成长正在刺激创新、鼓励投资并改善开发中国家患者的治疗效果。此外，政府支持和不断扩大的医疗保健基础设施正在加速市场渗透，使挽救生命的溶栓疗法更容易获得，最终有助于改善公共卫生并增强当地製药业的前景。

复合年增长率最高的地区：

在预测期内，由于人们对溶栓疗法的认识不断提高，预计北美将呈现最高的复合年增长率。医疗保健基础设施的进步、大型製药公司的存在以及支持性法律规范进一步推动了市场扩张。老年人口的增长和对微创治疗的需求将推动基于尿激酶的疗法的采用。这些因素的结合显着改善了患者的治疗效果，刺激了区域市场的成长和创新。

免费客製化服务

订阅此报告的客户可以选择以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球尿激酶市场类型

  • 尿激酶粉
  • 尿激酶溶液

6. 全球尿激酶市场（依来源）

  • 人类尿激酶
  • 重组尿激酶

7. 全球尿激酶市场（依给药途径）

  • 静脉
  • 导管内部

8. 全球尿激酶市场（依应用）

  • 肺动脉栓塞
  • 深层静脉栓塞症
  • 导管阻塞
  • 心肌梗塞
  • 其他用途

9. 全球尿激酶市场（依最终用户）

  • 医院
  • 专科诊所
  • 门诊手术中心
  • 其他最终用户

第十章全球尿激酶市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Syner-Med Ltd.
  • Microbix Biosystems Inc.
  • Wuxi Green Pharmaceutical Co., Ltd.
  • Jiangxi Haoran Bio-Pharma Co., Ltd.
  • Medicure Inc.
  • Lee's Pharmaceutical Holdings Ltd.
  • Taj Pharmaceuticals Limited
  • Jiangsu Techpool Bio-Pharma Co., Ltd.
  • Guangzhou Recomgen Biotech Co., Ltd.
  • LGM Pharma
  • ScienCell Research Laboratories, Inc.
  • BioVision, Inc.
  • Abbott Laboratories
  • Enzo Life Sciences, Inc.
  • Molecular Innovations, Inc.
  • Prospec-Tany Technogene Ltd.
  • Wuhan YZY Biopharma Co., Ltd.
  • GenScript Biotech Corporation
  • Chymotech AS
Product Code: SMRC29294

According to Stratistics MRC, the Global Urokinase Market is accounted for $2.08 billion in 2025 and is expected to reach $3.50 billion by 2032 growing at a CAGR of 7.7% during the forecast period. Urokinase is a thrombolytic enzyme used medically to dissolve blood clots in the body. It is a serine protease originally derived from human urine, but now commonly produced using recombinant DNA technology. Urokinase works by converting plasminogen to plasmin, an enzyme that breaks down fibrin, the primary protein component of blood clots. It is primarily used to treat conditions such as pulmonary embolism, deep vein thrombosis, and catheter blockages. As a fibrinolytic agent, urokinase plays a vital role in restoring blood flow in occluded vessels, making it a critical therapeutic option in emergency and interventional medicine.

According to 2024 article by British Heart Foundation, 7.6 million people are living in with heart and circulatory disease in UK.

Market Dynamics:

Driver:

Rising Prevalence of Thrombotic Disorders

The growing incidence of thrombotic disorders is propelling the urokinase market due to the heightened need for thrombolytic treatments. The enzyme urokinase, which is employed to break down blood clots, plays a vital role in the treatment of conditions like pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. As the global prevalence of these disorders rises, particularly among aging populations, the demand for effective clot-dissolving treatments is increasing. This trend is benefiting the urokinase market and spurring further developments in its production and application.

Restraint:

High Treatment Costs

High treatment costs significantly hinder the growth of the urokinase market by limiting accessibility for patients and healthcare providers, particularly in low- and middle-income regions. These elevated expenses reduce the adoption of urokinase-based therapies, as more affordable alternatives are sought. Additionally, high costs strain healthcare budgets, discourage insurance coverage, and restrict widespread clinical use, ultimately slowing market expansion and impeding innovation in thrombolytic treatments.

Opportunity:

Technological Advancements in Drug Delivery

Technological advancements in drug delivery systems have significantly impacted the Urokinase market by enhancing its therapeutic efficacy and precision. Innovations such as targeted delivery mechanisms and nanoparticle-based formulations ensure better bioavailability and reduced side effects. These advancements improve the drug's ability to target specific sites, optimizing the treatment of conditions like blood clots and heart attacks. Additionally, controlled release technologies and personalized drug delivery systems contribute to improved patient outcomes, driving demand and growth within the Urokinase market.

Threat:

Risk of Bleeding Complications

The risk of bleeding complications significantly hinders the growth of the urokinase market. Urokinase, a thrombolytic agent, carries a high potential for causing internal bleeding, particularly in patients with underlying conditions or on anticoagulants. This safety concern limits its widespread adoption among healthcare providers, prompting cautious prescription practices. Additionally, regulatory restrictions and the availability of safer alternatives further restrain market expansion, negatively impacting demand and overall market performance.

Covid-19 Impact

The COVID-19 pandemic significantly disrupted the urokinase market due to delays in elective surgeries, reduced hospital admissions, and supply chain interruptions. Demand for non-COVID-related therapies, including thrombolytic agents like urokinase, declined during the peak of the pandemic. However, as healthcare systems stabilized and surgical procedures resumed, the market began recovering. Additionally, increased awareness of thrombotic complications in COVID-19 patients indirectly supported demand for anticoagulant and thrombolytic therapies.

The urokinase solution segment is expected to be the largest during the forecast period

The urokinase solution segment is expected to account for the largest market share during the forecast period because Urokinase solutions, particularly in intravenous and local delivery forms, are gaining preference due to their ability to rapidly dissolve blood clots, improving patient outcomes in conditions like pulmonary embolism and deep vein thrombosis. The growing adoption of urokinase solutions in hospitals and healthcare facilities, combined with ongoing research, is further fueling the segment's positive impact on market expansion.

The deep vein thrombosis segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the deep vein thrombosis segment is predicted to witness the highest growth rate, due to the rising incidence of thrombotic disorders and increased awareness of early diagnosis and treatment. Urokinase, a thrombolytic agent, is widely used to dissolve blood clots in DVT patients, leading to its growing demand. Advancements in healthcare infrastructure and an aging population further contribute to market expansion. This trend positions DVT as a key driver fueling sustained growth and innovation in the urokinase market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising cardiovascular cases, increased awareness, and improved access to advanced therapies are driving demand. This growth is fostering innovation, encouraging investments, and improving patient outcomes across developing nations. Additionally, government support and expanding healthcare infrastructure are accelerating market penetration, making life-saving thrombolytic therapies more accessible, ultimately contributing to better public health and a stronger regional pharmaceutical landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to increasing awareness of thrombolytic therapies. Advancements in healthcare infrastructure, strong presence of key pharmaceutical players, and supportive regulatory frameworks further fuel market expansion. The growing geriatric population and demand for minimally invasive procedures enhance the uptake of urokinase-based treatments. Collectively, these factors are significantly improving patient outcomes and driving the regional market's growth and innovation.

Key players in the market

Some of the key players profiled in the Urokinase Market include Syner-Med Ltd., Microbix Biosystems Inc., Wuxi Green Pharmaceutical Co., Ltd., Jiangxi Haoran Bio-Pharma Co., Ltd., Medicure Inc., Lee's Pharmaceutical Holdings Ltd., Taj Pharmaceuticals Limited, Jiangsu Techpool Bio-Pharma Co., Ltd., Guangzhou Recomgen Biotech Co., Ltd., LGM Pharma, ScienCell Research Laboratories, Inc., BioVision, Inc., Abbott Laboratories, Enzo Life Sciences, Inc., Molecular Innovations, Inc., Prospec-Tany Technogene Ltd., Wuhan YZY Biopharma Co., Ltd., GenScript Biotech Corporation and Chymotech AS.

Key Developments:

In August 2024, Abbott and Medtronic announced a significant global partnership, to integrate Abbott's FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aims to enhance diabetes management by enabling automatic insulin adjustments based on real-time glucose data.

In June 2024, Abbott has partnered with the National Association of Community Health Centers (NACHC) to improve access to nutritious food and health services. The collaboration aims to enhance healthcare delivery and address the growing health challenges related to nutrition in underserved communities.

Types Covered:

  • Urokinase Powder
  • Urokinase Solution

Sources Covered:

  • Human-derived Urokinase
  • Recombinant Urokinase

Routes of Administration Covered:

  • Intravenous
  • Intracatheter

Applications Covered:

  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Catheter Occlusion
  • Myocardial Infarction
  • Other Application

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Urokinase Market, By Type

  • 5.1 Introduction
  • 5.2 Urokinase Powder
  • 5.3 Urokinase Solution

6 Global Urokinase Market, By Source

  • 6.1 Introduction
  • 6.2 Human-derived Urokinase
  • 6.3 Recombinant Urokinase

7 Global Urokinase Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intravenous
  • 7.3 Intracatheter

8 Global Urokinase Market, By Application

  • 8.1 Introduction
  • 8.2 Pulmonary Embolism
  • 8.3 Deep Vein Thrombosis
  • 8.4 Catheter Occlusion
  • 8.5 Myocardial Infarction
  • 8.6 Other Application

9 Global Urokinase Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Specialty Clinics
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Other End Users

10 Global Urokinase Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Syner-Med Ltd.
  • 12.2 Microbix Biosystems Inc.
  • 12.3 Wuxi Green Pharmaceutical Co., Ltd.
  • 12.4 Jiangxi Haoran Bio-Pharma Co., Ltd.
  • 12.5 Medicure Inc.
  • 12.6 Lee's Pharmaceutical Holdings Ltd.
  • 12.7 Taj Pharmaceuticals Limited
  • 12.8 Jiangsu Techpool Bio-Pharma Co., Ltd.
  • 12.9 Guangzhou Recomgen Biotech Co., Ltd.
  • 12.10 LGM Pharma
  • 12.11 ScienCell Research Laboratories, Inc.
  • 12.12 BioVision, Inc.
  • 12.13 Abbott Laboratories
  • 12.14 Enzo Life Sciences, Inc.
  • 12.15 Molecular Innovations, Inc.
  • 12.16 Prospec-Tany Technogene Ltd.
  • 12.17 Wuhan YZY Biopharma Co., Ltd.
  • 12.18 GenScript Biotech Corporation
  • 12.19 Chymotech AS

List of Tables

  • Table 1 Global Urokinase Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 4 Global Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 5 Global Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 6 Global Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 7 Global Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 8 Global Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 9 Global Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 10 Global Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 11 Global Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 12 Global Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 13 Global Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 14 Global Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 15 Global Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 16 Global Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 17 Global Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 18 Global Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 19 Global Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 20 Global Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 21 Global Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 22 North America Urokinase Market Outlook, By Country (2024-2032) ($MN)
  • Table 23 North America Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 24 North America Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 25 North America Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 26 North America Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 27 North America Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 28 North America Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 29 North America Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 30 North America Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 31 North America Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 32 North America Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 33 North America Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 34 North America Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 35 North America Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 36 North America Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 37 North America Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 38 North America Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 39 North America Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 40 North America Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 41 North America Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 42 North America Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 43 Europe Urokinase Market Outlook, By Country (2024-2032) ($MN)
  • Table 44 Europe Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 45 Europe Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 46 Europe Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 47 Europe Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 48 Europe Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 49 Europe Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 50 Europe Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 51 Europe Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 52 Europe Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 53 Europe Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 54 Europe Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 55 Europe Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 56 Europe Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 57 Europe Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 58 Europe Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 59 Europe Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 60 Europe Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 61 Europe Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 62 Europe Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 63 Europe Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 64 Asia Pacific Urokinase Market Outlook, By Country (2024-2032) ($MN)
  • Table 65 Asia Pacific Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 66 Asia Pacific Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 67 Asia Pacific Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 68 Asia Pacific Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 69 Asia Pacific Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 70 Asia Pacific Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 71 Asia Pacific Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 72 Asia Pacific Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 73 Asia Pacific Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 74 Asia Pacific Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 75 Asia Pacific Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 76 Asia Pacific Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 77 Asia Pacific Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 78 Asia Pacific Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 79 Asia Pacific Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 80 Asia Pacific Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 81 Asia Pacific Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 82 Asia Pacific Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 83 Asia Pacific Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 84 Asia Pacific Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 85 South America Urokinase Market Outlook, By Country (2024-2032) ($MN)
  • Table 86 South America Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 87 South America Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 88 South America Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 89 South America Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 90 South America Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 91 South America Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 92 South America Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 93 South America Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 94 South America Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 95 South America Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 96 South America Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 97 South America Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 98 South America Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 99 South America Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 100 South America Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 101 South America Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 102 South America Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 103 South America Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 104 South America Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 105 South America Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 106 Middle East & Africa Urokinase Market Outlook, By Country (2024-2032) ($MN)
  • Table 107 Middle East & Africa Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 108 Middle East & Africa Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 109 Middle East & Africa Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 110 Middle East & Africa Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 111 Middle East & Africa Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 112 Middle East & Africa Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 113 Middle East & Africa Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 114 Middle East & Africa Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 115 Middle East & Africa Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 116 Middle East & Africa Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 117 Middle East & Africa Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 118 Middle East & Africa Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 119 Middle East & Africa Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 120 Middle East & Africa Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 121 Middle East & Africa Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 122 Middle East & Africa Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 123 Middle East & Africa Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 124 Middle East & Africa Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 125 Middle East & Africa Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 126 Middle East & Africa Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)